LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade

被引:0
|
作者
Yi Liu
Brian Debo
Mingfeng Li
Zhennan Shi
Wanqiang Sheng
Yang Shi
机构
[1] Harvard Medical School,Division of Newborn Medicine and Epigenetics Program, Boston Children’s Hospital
[2] University of Oxford,Ludwig Institute for Cancer Research
[3] Yale School of Medicine,Department of Neuroscience and Kavli Institute for Neuroscience
[4] Zhejiang University School of Medicine,Institute of Immunology, and Department of Respiratory Disease of The First Affiliated Hospital
[5] Hangzhou,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Exhausted CD8+ T cells are key targets of immune checkpoint blockade therapy and their ineffective reinvigoration limits the durable benefit in some cancer patients. Here, we demonstrate that histone demethylase LSD1 acts to enforce an epigenetic program in progenitor exhausted CD8+ T cells to antagonize the TCF1-mediated progenitor maintenance and to promote terminal differentiation. Consequently, genetic perturbation or small molecules targeting LSD1 increases the persistence of the progenitor exhausted CD8+ T cells, which provide a sustained source for the proliferative conversion to numerically larger terminally exhausted T cells with tumor-killing cytotoxicity, thereby leading to effective and durable responses to anti-PD1 therapy. Collectively, our findings provide important insights into epigenetic mechanisms that regulate T cell exhaustion and have important implications for durable immunotherapy.
引用
收藏
相关论文
共 50 条
  • [31] Biomarkers of response to PD-1 inhibition in Merkel cell carcinoma
    Spassova, I
    Ugurel, S.
    Kubat, L.
    Terheyden, P.
    Hassel, J.
    Schadendorf, D.
    Becker, J. C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 5 - 5
  • [32] HETEROGENEITY OF PD-1HI T CELLS ASSOCIATES WITH RESPONSE TO PD-1 BLOCKADE IN HEPATOCELLULAR CARCINOMA
    Magen, Assaf
    Magen, Assaf
    Hamon, Pauline
    Schwartz, Myron
    Marron, Thomas
    Kamphorst, Alice
    Merad, Miriam
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A388 - A388
  • [33] KDM1A/ LSD1 inhibition enhances chemotherapy response in ovarian cancer
    Johnson, Jessica D.
    Chen, Yihong
    Jayamohan, Sridharan
    He, Yi
    Jamwal, Diksha
    Pandey, Neetesh
    Kost, Edward
    Vadlamudi, Ratna K.
    Sareddy, Gangadhara R.
    CANCER RESEARCH, 2024, 84 (06)
  • [34] LSD1 Histone Demethylase Assays and Inhibition
    Hayward, D.
    Cole, P. A.
    ENZYMES OF EPIGENETICS, PT A, 2016, 573 : 261 - 278
  • [35] KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer
    Chen, Yihong
    Johnson, Jessica D.
    Jayamohan, Sridharan
    He, Yi
    Venkata, Prabhakar P.
    Jamwal, Diksha
    Alejo, Salvador
    Zou, Yi
    Lai, Zhao
    Viswanadhapalli, Suryavathi
    Vadlamudi, Ratna K.
    Kost, Edward
    Sareddy, Gangadhara R.
    MOLECULAR CARCINOGENESIS, 2024, 63 (10) : 2026 - 2039
  • [36] LSD1 regulates PD-1 expression through interactions with Blimp-1 during acute viral infection
    Neeld, Dennis Kyle
    Bally, Alexander
    Majumder, Parimal
    Barwick, Benjamin
    Boss, Jeremy M.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [37] PD-1 is negatively regulated by LSD1 through interactions with Blimp-1 during acute viral infection
    Neeld, Dennis Kyle
    Bally, Alexander
    Lu, Peiyuan
    Majumder, Parimal
    Barwick, Benjamin
    Boss, Jeremy M.
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [38] LSD1 inhibition: a therapeutic strategy in cancer?
    Lynch, James T.
    Harris, William J.
    Somervaille, Tim C. P.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (12) : 1239 - 1249
  • [39] Biomarkers of response to PD-1/PD-L1 inhibition
    Vareki, Saman Maleki
    Garrigos, Carmen
    Duran, Ignacio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 116 - 124
  • [40] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84